| 31st week of 2013 patent applcation highlights part 39 |
| Patent application number | Title | Published |
|---|
| 20130195756 | 99mTc IMAGING AGENTS AND METHODS OF USE - An embodiment of the invention comprises a ligand of Formula I | 2013-08-01 |
| 20130195757 | SPARC BINDING APTAMERS AND USES THEREOF - The invention relates to nucleic acid aptamers having the ability to bind human SPARC protein (osteonectin) with specificity. The invention also relates to compositions including such aptamers, as well as methods of identifying such aptamers. The invention further relates to methods for using such aptamers in treating and diagnosing proliferative diseases such as, e.g., cancer. | 2013-08-01 |
| 20130195758 | PAA NANOPLATFORMS CONTAINING FLUOROPHORES AND TARGETED MOIETIES COVALENTLY LINKED AND PHOTOSENSITIZER POST-LOADED - A PAA nanoparticle containing a covalently linked fluorescent dye and a post-loaded tetrapyrrolic photosensitizer. | 2013-08-01 |
| 20130195759 | NANOSTRUCTURES SUITABLE FOR SEQUESTERING CHOLESTEROL AND OTHER MOLECULES - Articles, compositions, kits, and methods relating to nanostructures, including those that can sequester molecules such as cholesterol, are provided. Certain embodiments described herein include structures having a core-shell type arrangement; for instance, a nanoparticle core may be surrounded by a shell including a material, such as a lipid bilayer, that can interact with cholesterol and/or other lipids. In some embodiments, the structures, when introduced into a subject, can sequester cholesterol and/or other lipids and remove them from circulation. Accordingly, the structures described herein may be used to diagnose, prevent, treat or manage certain diseases or bodily conditions, especially those associated with abnormal lipid levels. | 2013-08-01 |
| 20130195760 | CHLOROTOXIN VARIANTS, CONJUGATES, AND METHODS FOR THEIR USE - Chlorotoxin variants, chlorotoxin variant conjugates, compositions that include the chlorotoxin variants or conjugates, and methods for using the chlorotoxin variants, conjugates, and compositions. | 2013-08-01 |
| 20130195761 | COMPOSITIONS COMPRISING ANTI-CAP37 ANTIBODIES AND METHODS OF PRODUCTION AND USE THEREOF - Compositions comprising antibodies raised against CAP37 and isoforms thereof, along with antigen binding fragments thereof, are disclosed. These compositions have many uses, such as in detection of CAP37 and as an early detection marker for various disease conditions. In addition, the compositions may be used therapeutically to inhibit, mitigate, or modulate certain cellular activities involving CAP37 or to monitor a disease progression or the success of a disease treatment. | 2013-08-01 |
| 20130195762 | FAT CELLS AND METHODS OF USING THEREOF - Beige cells that contain a reporter gene are disclosed herein. Such cells can be used to identify therapeutic agents for treatment of obesity and its associated disorders, such as diabetes. | 2013-08-01 |
| 20130195763 | METHODS AND COMPOSITIONS FOR IMPROVING SLEEP AND MEMORY - A method for determining whether a substance can increase the expression level of a fatty acid binding protein (FABP) in an animal. The method includes using a cell that includes an expression construct that comprises a FABP promoter operably linked to a polynucleotide sequence encoding a reporter molecule, wherein the cell is contacted with a candidate substance and then cultivating the cell under conditions conducive to expression of the reporter molecule. Increased expression of the construct in the presence of the candidate substance as compared to a control leads to improved sleep and long-term memory in the subject. | 2013-08-01 |
| 20130195764 | Nanoparticle Targeting to Ischemia for Imaging and Therapy - The invention provides compositions and methods that provide a solution to the difficulties in diagnosing ischemia, e.g., identifying specific affected anatomical areas, and treating ischemic tissue so as to minimize damage and promote healing of damaged tissue in a subject such as a human or other animal. | 2013-08-01 |
| 20130195765 | METHOD FOR TREATING AND DIAGNOSING CANCER BY USING CELL-DERIVED MICROVESICLES - Disclosed is a method for the treatment and/or diagnosis of cancer, using bacterial cell-derived microvesicles, which is highly effective in cancer therapy with a significant reduction in side effects. Also, a method is provided for delivering of a drug therapeutic or diagnostic for a disease, using bacterial cell-derived microvesicles loaded with the drug, thereby treating and diagnosing the disease effectively and specifically. | 2013-08-01 |
| 20130195766 | ULTRAFINE NANOPARTICLES COMPRISING A FUNCTIONALIZED POLYORGANOSILOXANE MATRIX AND INCLUDING METAL COMPLEXES; METHOD FOR OBTAINING SAME AND USES THEREOF IN MEDICAL IMAGING AND/OR THERAPY - The invention relates to novel biocompatible hybrid nanoparticles of very small size, useful in particular for diagnostics and/or therapy. | 2013-08-01 |
| 20130195767 | Magnetic Nanoparticles - A magnetic nanoparticle includes a magnetic core and a superparamagnetic outer shell, in which the outer shell enhances magnetic properties of the nanoparticle. The enhanced magnetic properties of the magnetic nanoparticle allow for highly sensitive detection as well as diminished non-specific aggregation of nanoparticles. | 2013-08-01 |
| 20130195768 | CEST SYSTEMS EXHIBITING A CONCENTRATION INDEPENDENT RESPONSIVENESS - The present invention relates to the use of non-equivalent mobile protons belonging to NMR distinguishable steroisomers of a CEST agent in a ratiometric based CEST imaging procedure and to Lanthanide (III) complex compounds displaying at least two NMR-distinguishable steroisomers in solution useful as concentration independent CEST responsive agents. | 2013-08-01 |
| 20130195769 | OLEAGINOUS PHARMACEUTICAL AND COSMETIC FOAM - The invention relates to stable oleaginous cosmetic or therapeutic foam compositions containing certain active agents, having unique therapeutic properties and methods of treatment using such compositions. The foamable composition includes at least one solvent selected from a hydrophobic solvent, a silicone oil, an emollient, a co-solvent, and mixtures thereof, wherein the solvent is present at a concentration of about 70% to about 96.5% by weight of the total composition, at least a non-ionic surface-active agent at a concentration of about 0.1% to less than about 10% by weight of the total composition; at least one gelling agent at a concentration of about 0.1% to about 5% by weight of the total composition; a therapeutically effective amount of at least one active agent; and at least one liquefied or compressed gas propellant, at a concentration of about 3% to about 25% by weight of the total composition. | 2013-08-01 |
| 20130195770 | COMPOSITION AND METHOD FOR REDUCING ATHEROSCLEROTIC LESIONS - The present invention relates to a method for reducing cholesterol absorption and the occurrence of atherosclerotic lesions in an animal comprising administering to the animal a composition comprising an effective amount of at least one cholesterol ester. | 2013-08-01 |
| 20130195771 | Gantrez Hydrogel With Dry Tack - A Gantrez hydrogel comprising sodium, calcium, zinc, strontium, and ferric cations, and a polyvinylpyrrolidone based tack agent is disclosed. A method for preparation of the Gantrez hydrogel is also disclosed. | 2013-08-01 |
| 20130195772 | COLOR CHANGE OF CHALCONE-CONTAINING ORAL CARE FORMULATIONS - Oral care compositions and methods are described in which the composition includes a chalcone color change component, which may be phenyl-3-methoxy-4-hydroxystyryl ketone. The color change component is induced to change colors by addition of saliva and/or by a change in pH of the composition. The composition and methods provide benefits including providing visual cues to the user. | 2013-08-01 |
| 20130195773 | COMPOSITIONS - Compositions, comprising menthofuran and selected menthol compounds which feature improved flavour and odour properties, are provided and, in addition, the production of compositions, specifically, of emulsions with an improved storage stability. | 2013-08-01 |
| 20130195774 | Processes Of Making Oral Compositions Containing Gel Networks - The present invention is directed towards a process for making oral compositions comprising gel networks. The gel networks are formed from a fatty amphiphile dispersion and swelling surfactant. The fatty amphiphile dispersion comprises one or more fatty amphiphiles, one or more dispersing surfactants, and one or more solvents. A gel network is formed when the fatty amphiphile dispersion is combined with the swelling surfactant. A method of preparing the fatty amphiphile dispersion and oral composition is included. | 2013-08-01 |
| 20130195775 | IONIC/IONOGENIC COMB COPOLYMER COMPOSITIONS AND PERSONAL CARE PRODUCTS CONTAINING THE SAME - Ionic and ionogenic comb copolymers are disclosed along with personal care products that employ them as a modifier that results in increased sensory attributes and increased effectiveness in the deposition of actives and can also act as a thickening agent. The copolymer includes one or more repeating units derived from olefinically unsaturated anionic or anionogenic or zwitterionic comonomers, and one or more repeating units having the formula | 2013-08-01 |
| 20130195776 | COSMETIC COMPOSITION BASED ON ELLAGIC ACID OR A DERIVATIVE THEREOF AND A BACTERIAL EXTRACT - The invention relates to a cosmetic composition comprising, in a cosmetically acceptable medium: (i) from 0.01% to 10% by weight, relative to the total weight of the composition, of one or more compounds chosen from ellagic acid, ethers thereof and ellagic acid salts or ethers thereof, in a content ranging (ii) one or more extracts of one or more non-photosynthetic, non-fruiting filamentous bacteria, and (iii) one or more surfactants chosen from anionic and/or amphoteric or zwitterionic surfactants. The invention also relates to a cosmetic treatment process using such a composition, and to the use of this composition for eliminating and/or reducing the amount of dandruff on the hair and the scalp. | 2013-08-01 |
| 20130195777 | HAIR TREATMENT COMPOSITION CONTAINING GAMBOGIC ACID, ESTER OR AMIDE - The present invention relates to a cosmetic composition comprising compounds or salts of formula (I) or formula (II), wherein R1 and R2 are both independently hydrogen (H), or a saturated, straight or branched C | 2013-08-01 |
| 20130195778 | COSMETIC COMPOSITION COMPRISING A POLYSILOXANE AND A POLYMER BOTH BEARING A HYDROGEN-BOND-GENERATING JOINING GROUP, AND COSMETIC TREATMENT PROCESS - The present invention relates to a cosmetic composition comprising: | 2013-08-01 |
| 20130195779 | SUBSTANTIVE SUNSCREEN FORMULATION - Disclosed is a substantive emulsion and methods for its use comprising 40 to 45% by weight of water, 25 to 30% by weight of a combination of octocrylene, avobenzone, octisalate, homosalate, and oxybenzone, and 3 to 5% by weight of a combination of VP eicosene copolymer, acrylates/C12-22 alkyl methacrylate copolymer, trimethylsiloxysilicate, and acrylates/dimethicone copolymer, wherein the emulsion has a sun protection factor of at least 50, and wherein the emulsion is very water resistant. | 2013-08-01 |
| 20130195780 | Skin Care Products Contianing Anatabine Or Derivative Thereof - A skin care product includes a compound of Formula I, IA, or IB (e.g., anatabine), or a salt thereof, and a suitable cosmetic or pharmaceutical vehicle. In some aspects, the skin care product is a paste, cream, lotion, gel, moisturizer, cleanser, or sunscreen. In some embodiments, the skin care product is applied topically to reduce inflammation, redness, and/or irritation, and/or to improve the appearance of the skin. In other embodiments, the skin care product is applied topically to treat an autoimmune and/or dermatological condition such as acne, psoriasis, and/or rosacea. | 2013-08-01 |
| 20130195781 | Modified Variant Bowman Birk Protease Inhibitors - The present invention relates to modified variant Bowman Birk Protease Inhibitor proteins (BBPIs) that comprise peptides that bind target proteins, and that are further modified to have greater protease inhibitory activity and/or be produced at greater yields than the unmodified BBPIs. The invention encompasses polynucleotide constructs and expression vectors containing polynucleotide sequences that encode the modified variant BBPIs, the transformed host cells that express and produce the modified variant BBPIs, the modified variant BBPI proteins, the compositions comprising the modified variant BBPIs, and the methods for making and using the modified variant BBPIs in personal care. | 2013-08-01 |
| 20130195782 | Novel Glycine Derivative Capable Of Inhibiting Melanin Formation And Composition Using The Same - The invention provides a glycine derivative, having a structure shown in the following general equation (I): | 2013-08-01 |
| 20130195783 | Methods For Smoothing Wrinkles and Skin Texture Imperfections - A skin smoothing composition that has from about 0.5 to about 4% sodium silicate as measured by silica content (SiO | 2013-08-01 |
| 20130195784 | WATER DISPERSIBLE SOLID DISPERSION OF PIGMENT - A solid dispersion of pigment for an aqueous composition includes a pigment and an ethoxylated alcohol. The solid dispersion of pigment is adapted for being directly incorporated into the aqueous composition with reduced shear for coloration. A method of preparing a solid dispersion of pigment for an aqueous composition with reduced shear mixing includes heating the mixture of an ethoxylated alcohol and a pigment, and cooling the mixture to obtain the solid dispersion of pigment. | 2013-08-01 |
| 20130195785 | ANTIPERSPIRANT EMULSION COMPOSITIONS AND PROCESSES FOR MAKING ANTIPERSPIRANT EMULSION COMPOSITIONS - Processes for making an antiperspirant emulsion composition and antiperspirant emulsion compositions are provided herein. In an embodiment, a process for making an antiperspirant emulsion composition includes combining water and an antiperspirant active component to form a water phase. A hydrophobic carrier and a structurant are combined to form an oil phase. The structurant has a melting point above ambient temperature. The oil phase is heated to a first temperature of at least a melting point of the structurant that is disposed in the oil phase. The water phase and the heated oil phase are mixed to form the antiperspirant emulsion composition. The antiperspirant emulsion composition is cooled under continued mixing. | 2013-08-01 |
| 20130195786 | SHAMPOO CONTAINING A GEL NETWORK - A shampoo composition comprising: i) a cleaning phase comprising a cleansing anionic surfactant which is a salt and comprises an alkyl group with from 8 to 14 carbons; ii) an aqueous conditioning gel network having no overall charge or is anionic, the gel network comprising: (a) fatty material; (b) a gel network anionic surfactant comprising an alkyl group with from 16 to 30 carbons; (c) cationic surfactant; and iii) an esterified sucrose. | 2013-08-01 |
| 20130195787 | Substituted Cellulose Acetates and Uses Thereof - The present invention relates to substituted cellulose acetates and methods of use thereof. One embodiment of the present invention provides a drilling fluid having a base fluid and a viscosifier having a substituted cellulose acetate having a polar substituent that comprises an oxygen atom covalently bonded to a nonmetal selected from the group of sulfur, phosphorus, boron, and chlorine; where the nonmetal is present in at least about 0.01% by weight of the substituted cellulose acetate. | 2013-08-01 |
| 20130195788 | HAIR FIXATIVES - Described are hair fixative compositions comprising an aqueous dispersion comprising an ethylene acrylic acid co-polymer, and optionally a metallocene catalyzed polyolefin. | 2013-08-01 |
| 20130195789 | LOW SWELL, LONG-LIVED HYDROGEL SEALANT - A low swell, long-lived hydrogel sealant formed by reacting a highly oxidized polysaccharide containing aldehyde groups with a multi-arm amine is described. The hydrogel sealant may be particularly suitable for applications requiring low swell and slow degradation, for example, ophthalmic applications such as sealing wounds resulting from trauma such as corneal lacerations, or from surgical procedures such as vitrectomy procedures, cataract surgery, LASIK surgery, glaucoma surgery, and corneal transplants; neurosurgery applications, such as sealing the dura; and as a plug to seal a fistula or the punctum. The low swell, long-lived hydrogel sealant may also be useful as a tissue sealant and adhesive, and as an anti-adhesion barrier. | 2013-08-01 |
| 20130195790 | SPINOSYN ANTIFOULING COMPOSITIONS, METHODS OF USE THEREOF AND ARTICLES PROTECTED FROM ATTACHMENT OF BIOFOULING ORGANISMS - Disclosed herein are antifouling compositions including at least one spinosyn active material. These compositions provide protection to surfaces coated or impregnated therewith from attachment of various biofouling organisms. Compositions include, for example, paint, varnish, and sealant formulations. | 2013-08-01 |
| 20130195791 | CONJUGATES COMPRISING AN N-OXIME BOND AND ASSOCIATED METHODS - Conjugates comprising a N-oxime bond are disclosed. In one embodiment, a suitable conjugate is represented by the following Formula (I): | 2013-08-01 |
| 20130195792 | METHOD OF TREATING INFLAMMATION - The present invention concerns methods of treating systemic, regional, or local inflammation from a patient suffering or at risk of inflammation comprising administration of a therapeutically effective dose of a sorbent that sorbs an inflammatory mediator in said patient. In some preferred embodiments, the sorbent is a biocompatible organic polymer. | 2013-08-01 |
| 20130195793 | RADIATION-CURABLE ANTIMICROBIAL COATINGS - The present invention relates to radiation-curable antimicrobial coatings, to a process for preparation thereof, and to the use thereof. | 2013-08-01 |
| 20130195794 | CANCER VACCINE - The disclosure relates to a vaccine including at least one adjuvant useful in the prevention and treatment of blood cancers, for example lymphoma, leukaemia or myeloma. | 2013-08-01 |
| 20130195795 | COMPOSITIONS AND METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES - Described herein are immunosuppressive molecules including immunosuppressive variants of IL-2, and use of such molecules to treat inflammatory and autoimmune disorders. | 2013-08-01 |
| 20130195796 | Inhibitors and Methods of Inhibiting Bacterial and Viral Pathogens - Compounds, pharmaceutical compositions and methods for treating viral and bacterial infections, by administering certain thiourea compounds, specifically acylthiourea, carboximidoylthiourea and S-alkyl isothiourea derivatives and analogs, in therapeutically effective amounts are disclosed. | 2013-08-01 |
| 20130195797 | HIGH POTENCY FORMULATIONS OF VX-950 - High potency pharmaceutical compositions comprising VX-950, sodium lauryl sulfate and a polymer selected from the group consisting of hypromellose acetate succinate-M, hypromellose acetate succinate-L and hypromellose acetate succinate-H. | 2013-08-01 |
| 20130195798 | COMBINATION THERAPY FOR TREATMENT OF VIRAL INFECTIONS - One can treat a viral infection by first administering at least one first antiviral compound for a first time period and then, after the end of the first time period, concurrently or subsequently administering the at least one first antiviral compound and at least one second antiviral compound for a second period. In some cases, after the end of the second period, the same at least one second antiviral compound that was administered during the second time period may be administered for a third time period without concurrent or subsequent administration of the at least one first antiviral compound. | 2013-08-01 |
| 20130195799 | SYNERGISTIC BIOMOLECULE-POLYMER CONJUGATES - The synergistic biomolecule-polymer conjugates are the long-acting, in vivo controlled continuous-release and hybrid synergy systems of biomolecules that provide increased biological activities and enhanced pharmacological properties for achieving greater therapeutic efficacies. | 2013-08-01 |
| 20130195800 | Vectors Conditionally Expressing Therapeutic Proteins, Host Cells Comprising the Vectors, and Uses Thereof - This invention relates to the field of therapeutics. Most specifically, the invention provides methods of generating conditionally expressing vectors for one or more immunomodulators under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals. These vector may be provided to treat a variety of disorders, e.g., neoplastic disorders, through direct injection or through in vitro engineered cells, such as dendritic cells. | 2013-08-01 |
| 20130195801 | CNS TARGETING AAV VECTORS AND METHODS OF USE THEREOF - The invention in some aspects relates to recombinant adeno-associated viruses useful for targeting transgenes to CNS tissue, and compositions comprising the same, and methods of use thereof. In some aspects, the invention provides methods and compositions for treating CNS-related disorders. | 2013-08-01 |
| 20130195802 | Cellular Constituents From Bacteroides, Compositions Thereof, and Therapeutic Methods Employing Bacteroides or Cellular Constituents Thereof - A cellular constituent is lysed from, produced by and/or isolated from one or more bacteria from the genus | 2013-08-01 |
| 20130195803 | BOVINE MILK OLIGOSACCHARIDES - Oligosaccharides from bovine milk, whey and dairy products, and methods of producing bovine milk oligosaccharides are provided. | 2013-08-01 |
| 20130195804 | COMPOSITIONS FOR FECAL FLORAL TRANSPLANTATION AND METHODS FOR MAKING AND USING THEM AND DEVICES FOR DELIVERING THEM - In alternative embodiments, the invention provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. In alternative embodiments, compositions and methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated traveler's diarrhea, or | 2013-08-01 |
| 20130195805 | MODIFICATION OF REACTIVITY OF BONE CONSTRUCTS - A method of enhancing the binding of growth factors and cell cultures to a demineralized allograft bone material which includes applying ex vivo an effective quantity of an ionic force change agent to at least a portion of the surface of a demineralized allograft bone material to produce a binding-sensitized demineralized allograft bone material and implanting the binding-sensitized demineralized allograft bone material into a host bone. The ionic force change agent may include at least one of enzymes, pressure, chemicals, heat, sheer force, oxygen plasma, supercritical nitrogen, supercritical carbon, supercritical water or a combination thereof. A molecule, a cell culture, or a combination thereof is administered to the binding-sensitized demineralized allograft bone material. | 2013-08-01 |
| 20130195806 | PHARMACEUTICAL PREPARATIONS OF HUMAN RPE CELLS AND USES THEREOF - This disclosure provides the first description of hESC-derived cells transplanted into human patients. Results are reported for one patient with each of Stargardt's Macular Dystrophy (SMD) and Dry Age-Related Macular Degeneration (AMD). Controlled hESC differentiation resulted in near-100% pure RPE populations. Immediately after surgery, hyperpigmentation was visible at the transplant site in both patients, with subsequent evidence the cells had attached and integrated into the native RPE layer. No signs of inflammation or hyperproliferation were observed. The hESC-derived RPE cells have shown no signs of rejection or tumorigenicity at the time of this report. Visual measurements suggest improvement in both patients. | 2013-08-01 |
| 20130195807 | AGONISTS OF GROWTH HORMONE RELEASING HORMONE AS EFFECTORS FOR SURVIVAL AND PROLIFERATION OF PANCREATIC ISLETS - Agonists of growth hormone releasing hormone promote islet graft growth and proliferation in patients. Methods of treating patients comprise the use of these agonists. | 2013-08-01 |
| 20130195808 | MESENCHYMAL STEM CELL AND A METHOD OF USE THEREOF - Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells. | 2013-08-01 |
| 20130195809 | MULTIPOTENT STEM CELLS AND USES THEREOF - The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The invention further provides a proliferative stem cell, which expresses genes including Oct-4, Nanog, Sox2, GDF3, P16INK4, BMI, Notch, HDAC4, TERT, Rex-1 and TWIST but does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The cells of the invention can be isolated from adult mammals, have embryonic cell characteristics, and can form embryoid bodies. Methods for obtaining the stem cells, as well as methods of treating diseases and the differentiated stem cells, are also provided. | 2013-08-01 |
| 20130195810 | MULTIPOTENT STEM CELLS AND USES THEREOF - The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The invention further provides a proliferative stem cell, which expresses genes including Oct-4, Nanog, Sox2, GDF3, P16INK4, BMI, Notch, HDAC4, TERT, Rex-1 and TWIST but does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The cells of the invention can be isolated from adult mammals, have embryonic cell characteristics, and can form embryoid bodies. Methods for obtaining the stem cells, as well as methods of treating diseases and the differentiated stem cells, are also provided. | 2013-08-01 |
| 20130195811 | Biomatrix Scaffolds - The present invention provides biomatrix scaffolds, a tissue extract enriched for extracellular matrix components and bound growth factors, cytokines and hormones, and methods of making and using same. | 2013-08-01 |
| 20130195812 | INDUCED PLURIPOTENT STEM CELLS - Described herein is a major breakthrough in nuclear reprogramming and induced pluripotent stem cell (iPSC) technology. Fusion of the powerful transcription activation domain (TAD) of MyoD to the Oct4 protein makes iPSCs generation faster, more efficient, purer, safer and feeder-free. Also, disclosed herein is the first report of the use of a TAD fused to a transcription factor as a method for making iPSCs. By combining transcription factors and TADs, this approach to nuclear reprogramming can have a range of applications from inducing pluriopotency to inducing transdifferentiation without transitioning through iPSCs. | 2013-08-01 |
| 20130195813 | METHOD FOR PRODUCING CELLS HAVING CHARACTERISTICS OF HEPATOCYTES - The present invention relates to a method of producing cells having at least one characteristic of human hepatocytes as well as to cells produced by said method and uses of these cells. | 2013-08-01 |
| 20130195814 | TISSUE-SPECIFIC DIFFERENTIATION MATRICES AND USES THEREOF - In some aspects, this invention provides a method of making a bone marrow-derived tissue-specific stem cell proliferation, expansion, isolation and rejuvenation extracellular matrix. In other aspects, this invention provides a method of making a tissue-specific fibroblast-derived stem cell differentiation extracellular matrix. Also provided are methods of using such a cell-derived preservation or differentiation matrices to induce tissue-specific differentiation of pluripotent cells, repair damaged tissue, and treat a subject having a physiologic deficiency using the same. | 2013-08-01 |
| 20130195815 | METHOD FOR LABELING INSULIN-SECRETING PANCREATIC BETA CELLS AND OBTAINING PURIFIED INSULIN-SECRETING PANCREATIC B-CELLS AND AN INSULIN REPORTED - A method for labeling insulin-secreting pancreatic β-cells in human islets by using a genetically-encoded preproinsulin fluorescent protein reporter which targets an insulin fusion protein to correct insulin vesicles. The reporter system comprising an insulin and fluorescent protein construct provides real time tracking of secretory granules in live cells and allows for the accurate measuring of the level of secretion. The labeled cells are sorted by fluorescence-activated cell sorting to obtain purified insulin-secreting pancreatic β-cell pools from human islets. The β-cell pools are suitable for transplantation into the pancreas of diabetics in order to treat diabetes. | 2013-08-01 |
| 20130195816 | COMPOSITIONS TO EFFECT NEURONAL GROWTH - Compositions containing neurogenic agents for inhibition of neuron death and inducing proliferation of neural cells are disclosed. | 2013-08-01 |
| 20130195817 | METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS AND VASCULOGENESIS - Disclosed herein are methods and compositions for stimulating angiogenesis, using cells descended from marrow adherent stromal cells that have been transfected with sequences encoding a Notch intracellular domain. Applications of these methods and compositions include treatment of ischemic disorders such as stroke. | 2013-08-01 |
| 20130195818 | METHOD OF PRODUCING MYELOID BLOOD CELLS - An object of the present invention is to provide a method of producing a myeloid blood cell possessing a proliferative capability. According to the present invention, provided is a method of producing a myeloid blood cell possessing a proliferative capability, including forcedly expressing (A) a cMYC gene, and (B) at least one gene selected from the group consisting of a BMI1 gene, an EZH2 gene, an MDM2 gene, an MDM4 gene, and an HIF1A gene in a myeloid blood cell. | 2013-08-01 |
| 20130195819 | T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE - The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for a cancer antigen, e.g., a renal cell carcinoma antigen, wherein the TCR recognizes the cancer antigen in a major histocompatibility complex (MHC)-independent manner. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host using the inventive TCRs or related materials. | 2013-08-01 |
| 20130195820 | USE OF BLOOD GROUP STATUS III - The present invention relates to a microbial composition which is tailored based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from the intestine of secretor individuals. The present invention further relates to a method of tailoring a microbial composition based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from that of secretor blood group status. The present invention relates to use of the secretor status of an individual as a criterion for microbial supplementation tailored based on the differences in the spectra of microbes found between secretor and non-secretor individuals. | 2013-08-01 |
| 20130195821 | Treatment of IBD and IBS Using Both Probiotic Bacteria and Fermented Cereal as Treatment Effectors - The invention covers a novel treatment strategy that considerably improves conventional probiotic treatments of inflammatory bowel diseases, irritable bowel syndrome and other gastrointestinal disorders. Both probiotic microorganisms and the carrier of the probiotic microorganisms in form of a fermented cereal gruel are used as treatment effectors. Phospholipids may also be an effector. The novel treatment strategy is capable of removing the symptoms of inflammatory bowel diseases regardless of a mild, moderate or severe stage of the disease. | 2013-08-01 |
| 20130195822 | Probiotic Strains for Use in Improving the Enteric Nervous System - The invention relates to the use of lactic acid bacteria, for use in modifying the enteric nervous system and more particularly in treating and/or preventing intestinal disorders such as constipation and/or irritable bowel disease. | 2013-08-01 |
| 20130195823 | USE OF LACTOBSCILLI INHIBITING GAS PRODUCTS COLIFORM BACTERIA ISOLATED FROM INFANTS AFFECTED BY COLIC - The present invention relates to a composition comprising two probiotic strains of bacteria capable of performing an antioxidant and/or antibacterial and competitive action against species of coliform bacteria that produce gas by fermentation of sugar, in particular lactose, isolated from infants affected by colic. | 2013-08-01 |
| 20130195824 | Methods for Reducing Cholesteron Using Bacillus Coagulans Spores, Systems and Compositions - The invention describes therapeutic compositions including a lactic acid-producing bacteria, such as isolated | 2013-08-01 |
| 20130195825 | Cells expressing Th1 characteristics and cytolytic properties - A novel cell type has been generated that has both Th1 characteristics and cytolytic activity. These Th1/killer cells are CD4+ cells purified from peripheral blood and manipulated to have Th1 characteristics such as production of IFN-gamma combined with cytolytic activity similar to cytotoxic T-cells (CTL). The CTL activity is targeted toward diseased cells, not normal cells. The cytolytic activity of the Th1/killer cells is mediated by Granzyme B-Perforin mechanism and results in apoptotic death of diseased cells. Methods of producing and using these Th1/killer cells include isolating CD4+ cells from peripheral blood, activating the CD4+ T-cells to form Th1/killer cells and administering these Th1/killer cells with the cytolytic activity to a patient wherein the Th1/killer cells are allogeneic to the patient. | 2013-08-01 |
| 20130195826 | COMPOSITION COMPRISING BACILLUS - The present invention refers to a composition comprising | 2013-08-01 |
| 20130195827 | NUTRIGENOMIC METHODS TO OVERCOME CARBOHYDRATE BINGEING AND OVEREATING - This invention concerns Reward Deficiency Syndrome (RDS) and obesity, and the role of catecholaminergic pathways in aberrant substance-seeking behavior, in particular cravings for carbohydrates. Also described are new nutrigenomic formulas having unique combinations of ingredients having a generalized anti-craving effect are, which can inhibit carbohydrate bingeing, inducing significant healthy fat loss and relapse prevention, as well genetic testing for certain polymorphisms correlated with RDS behaviors. | 2013-08-01 |
| 20130195828 | Pharmaceutical Compositions and Methods for Digesting Atherosclerotic Plaques - Disclosed are pharmaceutical compositions and methods for digesting atherosclerotic plaques in a patient in need thereof. The compositions include and the methods utilize a mixture of collagenases for digesting plaques and optionally may include or utilize additional agents such as cyclodextrins, chelating agents, and tissue plasminogen activator. | 2013-08-01 |
| 20130195829 | Themostable Phytase Variants - The present invention relates to a method for producing phytase variants which has at least 74% identity to a phytase derived from | 2013-08-01 |
| 20130195830 | PERORALLY APPLICABLE PREPARATION CONTAINING HISTAMINASE OF VEGETABLE ORIGIN, RESISTANT TO PEPSIN AND TRYPSIN AND A PROCESS FOR PRODUCING IT - The subject of the invention is a perorally applicable preparation of vegetable origin, resistant to pepsin and trypsin, based on histaminase, optionally for the use as an agent for improving digestion, reducing appetite or reducing body weight. The preparation of the invention is a pressed juice—which is optionally in lyophilized form—obtained from seedlings of pea ( | 2013-08-01 |
| 20130195831 | SILK-BASED DRUG DELIVERY SYSTEM - The present invention provides for novel sustained release silk-based delivery systems. The invention further provides methods for producing such formulations. In general, a silk fibroin solution is combined with a therapeutic agent to form a silk fibroin article. The article is then treated in such a way as to alter its conformation. The change in conformation increases its crystallinity or liquid crystallinity, thus controlling the release of a therapeutic agent from the formulation. This can be accomplished as single material carriers or in a layer-by-layer fashion to load different therapeutic agents or different concentrations of these agents in each layer. | 2013-08-01 |
| 20130195832 | INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF PHENYLALANYL-ALPHA-TRNA SYNTHETASES - Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. | 2013-08-01 |
| 20130195833 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SYMPTOMS OF PRION DISEASES - A therapeutic composition for the treatment of the symptoms of prion diseases and the method for preparing the therapeutic agents is disclosed. The therapeutic composition is a stable pharmaceutical composition comprising one or more digestive and/or pancreatic enzymes. The therapeutic composition may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic composition may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as a biomarker for the presence of a prion disease, or the likelihood of an individual to develop a prion disease is disclosed. | 2013-08-01 |
| 20130195834 | TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE II - Methods of treating glycogen storage disease type II, by administering acid α-glucosidase, are described, as are compositions for use in treatment of glycogen storage disease type II. | 2013-08-01 |
| 20130195835 | Glycosylation of Molecules - Described herein are methods and genetically engineered cells useful for producing an altered N-glycosylation form of a target molecule. Also described are methods and molecules with altered N-glycosylation useful for treating a variety of disorders such as metabolic disorders. | 2013-08-01 |
| 20130195836 | MANNOSE RECEPTOR C TYPE 1 (MRC1) CODON OPTIMIZED CELL LINE AND USES THEREOF - Described herein are isolated nucleic acid molecules comprising nucleotide sequence encoding mannose receptor, C type 1 (MRC1) wherein the 5′ region of the nucleotide sequence encoding MRC1 is codon optimized; cells comprising such nucleic acid molecules; and methods of detecting antibody production, e.g., neutralizing antibody production, in a subject being treated for Gaucher disease using such cells. | 2013-08-01 |
| 20130195837 | METHODS FOR THE PREVENTION OR TREATMENT OF VESSEL OCCLUSION INJURY - This invention provides methods of preventing or treating cardiac ischemia-reperfusion injury in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to a subject in need thereof, wherein the peptide is D-Arg-2 6-Dmt-Lys-Phe-NH2 (SS-31). | 2013-08-01 |
| 20130195838 | Methods of Treating Cancer Using Growth Factor Retargeted Endopeptidases - The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer in a mammal using such TVEMP compositions. | 2013-08-01 |
| 20130195839 | Polymer-Based Compositions and Conjugates of Antimicrobial Agents - Provided herein are water-soluble polymer conjugates and polymer-based compositions of antimicrobial agents. Also provided are methods for synthesizing and administering such conjugates and compositions. | 2013-08-01 |
| 20130195840 | THERAPEUTICS AND PROCESSES FOR TREATMENT OF IMMUNE DISORDERS - Processes of diagnosing or treating an autoimmune abnormality are provided whereby the presence of IgA anti-neutrophil cytoplasmic antibodies (ANCA) in a subject are detected correlating with both presence and severity of disease such as Wegener's granulomatosis (WG). The FCAR genotype predicts whether IgA ANCA will be stimulatory or inhibitory of neutrophil activation such that in subjects with an inhibitory genotype, IgA ANCA will act as an inhibitor of disease severity, and in subjects with a proinflammatory genotype, IgA ANCA will increase disease severity as observed by increased prevalence of renal disease in WG. Thus, individualized medical treatment is possible based on determination of the presence of IgA ANCA and FCAR genotype. | 2013-08-01 |
| 20130195841 | BIOFILM RESISTANT MATERIALS - This invention provides a biofilm resistant material comprising an active agent, which active agent consists essentially of an insoluble copper oxide at a concentration of between 3 and 10% w/w of said biofilm resistant material and uses thereof. | 2013-08-01 |
| 20130195842 | Methods for treating disorders of amino acid metabolism - The invention is directed to methods for treating disorders of amino acid metabolism, in particular, phenylketonuria (PKU). Such methods utilize novel compositions including Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) alone or in combination with other agents or treatment modalities. | 2013-08-01 |
| 20130195843 | Biomarkers for Non-Hodgkin Lymphomas and Uses Thereof - The disclosure provides a method of identifying a subject as having B-cell non-Hodgkin lymphoma (NHL) such as testing a sample from a subject for a mutation in one or more biomarkers. Also described are methods for classifying or monitoring a subject having, or suspected of having, B-cell non-Hodgkin lymphoma comprising testing the sample for a mutation in one or more biomarkers. | 2013-08-01 |
| 20130195844 | ANTIBODIES AGAINST HUMAN IL17 AND USES THEREOF - An antibody binding to IL-17 characterized by binding to the same IL-17 epitope to which monoclonal antibody 3C1 binds, and being of human IgG1 isotype modified in the hinge region at amino acid position 216-240, preferably at amino acid position 220-240, between C | 2013-08-01 |
| 20130195845 | ANTI-ERBB2 ANTIBODIES - Anti-ErbB2 antibodies are described which bind to an epitope in Domain 1 of ErbB2 and induce cell death via apoptosis. Various uses for these antibodies are also described. | 2013-08-01 |
| 20130195846 | COMBINATION THERAPY WITH TYPE I AND TYPE II ANTI-CD20 ANTIBODIES - The present invention is directed to a combination therapy involving a type I anti-CD20 antibody and a type II anti-CD20 antibody for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. An aspect of the invention is a composition comprising a type I anti-CD20 antibody and a type II anti-CD20 antibody. Another aspect of the invention is a kit comprising a type I anti-CD20 antibody and a type II anti-CD20 antibody. Yet another aspect of the invention is a method for the treatment of a patient suffering from cancer comprising co-administering, to a patient in need of such treatment, a type I anti-CD20 antibody and a type II anti-CD20 antibody. | 2013-08-01 |
| 20130195847 | TREATMENT WITH ANTI-VEGF ANTIBODIES - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents. | 2013-08-01 |
| 20130195848 | IMIDAZOPYRAZINES - The present invention relates to imidazopyrazine compounds of general Formula (I): in which X, R | 2013-08-01 |
| 20130195849 | Stable Heterodimeric Antibody Design with Mutations in the Fc Domain - The provided scaffolds have heavy chains that are asymmetric in the various domains (e.g. CH2 and CH3) to accomplish selectivity between the various Fc receptors involved in modulating effector function, beyond those achievable with a natural homodimeric (symmetric) Fc molecule, and increased stability and purity of the resulting variant Fc heterodimers. These novel molecules comprise complexes of heterogeneous components designed to alter the natural way antibodies behave and that find use in therapeutics. | 2013-08-01 |
| 20130195850 | CD3 IMMUNOTHERAPEUTICS AND USES THEREOF - The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B cell related autoimmune, inflammatory, or hyperproliferative diseases. | 2013-08-01 |
| 20130195851 | ARTICLES OF MANUFACTURE AND METHODS FOR CO-ADMINISTRATION OF ANTIBODIES - The present invention relates to articles of manufacture and methods for co-administration of antibodies and/or antibody-like molecules, and further concerns methods for intravenous administration of more than one antibody and/or antibody-like molecule to a subject in need from a stable mixture contained in the same article of manufacture, such as an intravenous infusion bag (IV bag). | 2013-08-01 |
| 20130195852 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) - Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile. | 2013-08-01 |
| 20130195853 | MODULATORS OF CANDIDA HYPHAL MORPHOGENESIS AND USES THEREOF - The invention relates to modulation of fungal morphology between yeast-to-hyphal growth transition by controlling muramyl-L-alanine concentration and uses thereof. | 2013-08-01 |
| 20130195854 | PREDICTIVE BIOMARKER FOR CANCER TREATMENT WITH ADCC-ENHANCED ANTIBODIES - The present invention is directed to methods for identifying which patients diagnosed with cancer will most benefit from treatment with an anti-cancer therapy comprising an ADCC-enhanced antibody. | 2013-08-01 |
| 20130195855 | METHODS OF ANTAGONIZING SIGNAL TRANSDUCTION IN DORSAL ROOT GANGLION CELLS - Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated. | 2013-08-01 |
